Skip to main content
. 2014 Jul;5(7-8):240–249. doi: 10.18632/genesandcancer.22

Table 1. Primers targeting human integrins, E-cadherin and vimentin.

Target Forward primer (5'-3') Reverse primer (5'-3')
Alpha1 GGTTCCTACTTTGGCAGTATT AACCTTGTCTGATTGAGAGCA
Alpha2 GGAACGGGACTTTCGCAT GGTACTTCGGCTTTCTCATCA
Alpha3 AAGGGACCTTCAGGTGCA TGTAGCCGGTGATTTACCAT
Alpha6 TTGAATATACTGCTAACCCCG TCGAAACTGAACTCTTGAGGATAG
Alpha7 CTGTTTCAGCTACATTGCAGTC GCCTGGTGCTTGGGTTCT
AlphaV AATCTTCCAATTGAGGATATCAC AAAACAGCCAGTAGCAACAAT
Beta1 GAAGGGTTGCCCTCCAGA GCTTGAGCTTCTCTGCTGTT
Beta4 AGACGAGATGTTCAGGGACC GGTCTCCTCTGTGATTTGGAA
Beta5 GGAGCCAGAGTGTGGAAACA GAAACTTTGCAAACTCCCTC
Beta6 TCAGCGTGACTGTGAATATCC GTGACATTTGGAGCTGTTCAC
Beta8 AATTTGGTAGTGGAAGCCTATC GTCACGTTTCTGCATCCTTC
Actin GCTGTGCTACGTCGCCCTG GGAGGAGCTGGAAGCAGCC
CycloA CTCGAATAAGTTTGACTTGTGTTT CTAGGCATGGGAGGGAACA
E-Cadherin ACAGCCCCGCCTTATGATT TCGGAACCGCTTCCTTCA
Vimentin AAGAGAACTTTGCCGTTGAA GTGATGCTGAGAAGTTTCGT